Modeling risk for severe adverse outcomes using angiogenic factor measurements in women with suspected preterm preeclampsia

Prenatal Diagnosis

Volumn 35, Issue 4, 2015, Pages 386-393

  Palomaki, Glenn E ^a,b   Haddow, James E ^a,b   Haddow, Hamish R M ^b   Salahuddin, Saira ^c,d   Geahchan, Carl ^c   Cerdeira, Ana Sofia ^c,e   Verlohren, Stefan ^f   Perschel, Frank H ^f   Horowitz, Gary ^c,d   Thadhani, Ravi ^d,g   Karumanchi, S Ananth ^c,d,h   Rana, Sarosh ^c,d,i  

^a BROWN UNIVERSITY   (United States)

^b Savjani Institute for Health Research   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e Charité University Medicine ^*  (Portugal)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h HOWARD HUGHES MEDICAL INSTITUTE   (United States)

ⁱ UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1; BIOLOGICAL MARKER; FLT1 PROTEIN, HUMAN; PGF PROTEIN, HUMAN; PLACENTA PROTEIN;

ADVERSE OUTCOME; ARTICLE; DISEASE SEVERITY; DISEASE SURVEILLANCE; EMERGENCY HEALTH SERVICE; FEMALE; FETUS OUTCOME; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; PREECLAMPSIA; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; RISK ASSESSMENT; ADULT; BLOOD; NEWBORN; PRE-ECLAMPSIA; PREGNANCY;

ADULT; ANGIOGENESIS INDUCING AGENTS; BIOMARKERS; FEMALE; HUMANS; INFANT, NEWBORN; PLACENTA GROWTH FACTOR; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY PROTEINS; RISK ASSESSMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84926258773     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.4554     Document Type: Article

References (39)

1. Organization WH. World Health Report. Make every mother and child count. Geneva, 2005.
2. Friedman SA, Schiff E, Kao L, et al. Neonatal outcome after preterm delivery for preeclampsia. Am J Obstet Gynecol 1995;172:1785-8; discussion 1788-1792.
3. Thangaratinam S, Gallos ID, Meah N, et al. How accurate are maternal symptoms in predicting impending complications in women with preeclampsia? A systematic review and meta-analysis. Acta Obstet Gynecol Scand 2011;90:564-73.
4. Thangaratinam S, Ismail KM, Sharp S, et al. Accuracy of serum uric acid in predicting complications of pre-eclampsia: a systematic review. BJOG 2006;113:369-78.
5. Thangaratinam S, Koopmans CM, Iyengar S, et al. Accuracy of liver function tests for predicting adverse maternal and fetal outcomes in women with preeclampsia: a systematic review. Acta Obstet Gynecol Scand 2011;90:574-85.
6. Fisher KA, Luger A, Spargo BH, et al. Hypertension in pregnancy: clinical-pathological correlations and remote prognosis. Medicine (Baltimore) 1981;60:267-76.
7. Germain S, Nelson-Piercy C. Lupus nephritis and renal disease in pregnancy. Lupus 2006;15:148-55.
8. Catalano PM. Management of obesity in pregnancy. Obstet Gynecol 2007;109:419-33.
9. Powe CE, Thadhani R. Diabetes and the kidney in pregnancy. Semin Nephrol 2011;31:59-69.
10. American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013;122:1122-31.
11. Ganzevoort W, Rep A, de Vries JI, et al. Prediction of maternal complications and adverse infant outcome at admission for temporizing management of early-onset severe hypertensive disorders of pregnancy. Am J Obstet Gynecol 2006;195:495-503.
12. Menzies J, Magee LA, Macnab YC, et al. Current CHS and NHBPEP criteria for severe preeclampsia do not uniformly predict adverse maternal or perinatal outcomes. Hypertens Pregnancy 2007;26:447-62.
13. Schnettler WT, Dukhovny D, Wenger J, et al. Cost and resource implications with serum angiogenic factor estimation in the triage of pre-eclampsia. BJOG 2013;120:1224-32.
14. Thadhani R, Kisner T, Hagmann H, et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 2011;124:940-50.
15. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-58.
16. Chaiworapongsa T, Romero R, Espinoza J, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol 2004;190:1541-7; discussion 1547-1550.
17. Tsatsaris V, Goffin F, Munaut C, et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 2003;88:5555-63.
18. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-83.
19. Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008;21:9-23.
20. Kusanovic JP, Romero R, Chaiworapongsa T, et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 2009;22:1021-38.
21. Cerdeira AS, Karumanchi SA. Angiogenic proteins as aid in the diagnosis and prediction of preeclampsia. Scand J Clin Lab Invest Suppl 2010;242:73-8.
22. Chaiworapongsa T, Romero R, Savasan ZA, et al. Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med 2011;24:1187-207.
23. Rana S, Powe CE, Salahuddin S, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012;125:911-9.
24. Moore AG, Young H, Keller JM, et al. Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia. J Matern Fetal Neonatal Med 2012;25:2651-7.
25. Rana S, Schnettler WT, Powe C, et al. Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy 2013;32:189-201.
26. Sibiude J, Guibourdenche J, Dionne MD, et al. Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction. PLoS One 2012;7:e50208.
27. Chappell LC, Duckworth S, Seed PT, et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation 2013;128:2121-31.
28. Rana S, Cerdeira AS, Wenger J, et al. Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia. PLoS One 2012;7:e48259.
29. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 2002;99:159-67.
30. Verlohren S, Galindo A, Schlembach D, et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010;202:161.e1-11.
31. Haddow JE, Palomaki GE, Canick JA, Knight GJ. Prenatal screening for open neural tube defects and Down's syndrome. In Fetal Medicine: Basic Science and Clinical Practice, Rodeck CH, Whittle MJ (eds). Churchill Livingstone: London, 2009;243-64.
32. Neveux LM, Palomaki GE, Larrivee DA, et al. Refinements in managing maternal weight adjustment for interpreting prenatal screening results. Prenat Diagn 1996;16:1115-9.
33. Chaiworapongsa T, Romero R, Korzeniewski SJ, et al. Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study. J Matern Fetal Neonatal Med 2014;27:132-44.
34. Verlohren S, Herraiz I, Lapaire O, et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol 2012;206:58.e1-8.
35. Verlohren S, Herraiz I, Lapaire O, et al. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension 2014;63:346-52.
36. Palomaki GE, Haddow JE. Maternal serum alpha-fetoprotein, age, and Down syndrome risk. Am J Obstet Gynecol 1987;156:460-3.
37. Perni U, Sison C, Sharma V, et al. Angiogenic factors in superimposed preeclampsia: a longitudinal study of women with chronic hypertension during pregnancy. Hypertension 2012;59:740-6.
38. Rolfo A, Attini R, Nuzzo AM, et al. Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers. Kidney Int 2013;83:177-81.
39. Lai J, Garcia-Tizon Larroca S, Peeva G, et al. Competing risks model in screening for preeclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks' gestation. Fetal Diagn Ther 2014;35:240-8.